Metis TechBio Secures Billion-Dollar Drug Delivery Deal With Eli Lilly

The collaboration integrates Metis’s proprietary AI-driven platform, which specializes in the discovery and optimization of ionizable lipids, with the extensive pharmaceutical infrastructure of Indianapolis-based Eli Lilly. By improving the precision of these delivery vehicles, the companies intend to enhance the biodistribution of complex therapeutic modalities, addressing persistent challenges in drug targeting.

Financial terms confirm an initial payment to Metis in the low double-digit millions. Beyond this entry stake, the company stands to gain nearly $1.1 billion tied to rigorous development, regulatory, and commercial milestones. Future success will also trigger a tiered royalty structure on any resulting product sales, marking a significant milestone for the Hong Kong-listed developer.